Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer

Yeruva, Sri Lakshmi Hyndavi; Nwabudike, Stanley Madu; Ogbonna, Onyekachi Henry; O'Neal, Patricia

doi:10.1155/2015/784783

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer (PCa) survival has improved significantly over the last decade. More than 84% of men now survive 10 years or more in the UK [1] and the number of survivors is growing by 3% every year [2] . Globally, more than 1.1 million cases of PCa were recorded in 2012.…”

Section: Introductionmentioning

confidence: 99%

Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer

et al. 2018

View full text Add to dashboard Cite

AimsTo identify symptom clusters and predisposing factors associated with long-term symptoms and health-related quality of life after radiotherapy in men with prostate cancer.Materials and methodsPatient-reported outcomes (PROs) data from the Medical Research Council RT01 radiotherapy with neoadjuvant androgen deprivation therapy trial of 843 patients were used. PROs were collected over 5 years with the University of California, Los Angeles Prostate Cancer Index (UCLA-PCI) and the 36 item Short-Form Health Survey (SF-36). Symptom clusters were explored using hierarchical cluster analysis. The association of treatment dose, baseline patient characteristics and early symptom clusters with the change in severity of PROs over 3 years was investigated with multivariate linear mixed effects models.ResultsSeven symptom clusters of three or more symptoms were identified. The clusters were stable over time. The longitudinal profiles of symptom clusters showed the onset of acute symptoms during treatment for all symptom clusters and significant recovery by 6 months. Some clusters, such as physical health and sexual function, were adversely affected more than others by androgen deprivation therapy, and were less likely to return to pretreatment levels over time. Older age was significantly associated with decreased long-term physical function, physical health and sexual function (P < 0.001). Both baseline and acute symptom clusters were significant antecedents for impaired function and health-related quality of life at 3 years.ConclusionsMen with poorer physical function and health before or during treatment were more likely to report poorer PROs at year 3. Early assessment using PROs and lifestyle interventions should be used to identify those with higher needs and provide targeted rehabilitation and symptom management.

show abstract

Section: Introductionmentioning

confidence: 99%

Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, we do not understand the mechanism by which serum levels of estradiol in the male patients with PV were also lower than those in patients with RE. There is a rare case report showing the relationship between estrogen and polycythemia [16]. Estrogen is usually produced from testosterone during the aromatase activation.…”

Section: Serum Levels Of Testosterone Might Be Down-regulated By Negative Feedbackmentioning

confidence: 99%

Serum Levels of Testosterone in Patients with Polycythemia Vera

Fujita¹,

Ohwada²,

Nishimura³

2016

OJBD

View full text Add to dashboard Cite

Despite its association with vascular events such as myocardial and cerebral infarction, polycythemia vera (PV) is characterized by low serum total cholesterol levels. Because several sex hormones are derived from cholesterol, statins may induce hypogodanism in male patients. Therefore, we assessed the relationship between serum total cholesterol and sex hormone levels according to gender. Medical records of 41 patients with erythrocytosis (hemoglobin concentrations: men >18.5 g/dL; women >16.5 g/dL) collected between August 2005 and December 2014 were reviewed for patient age, and gender, as well as clinical hematology, biochemistry, and endocrinology laboratory findings. Serum levels of testosterone were lower in men with PV than in patients with reactive erythrocytosis (RE) (PV: 385 ± 78 ng/mL versus RE: 529 ± 46 ng/mL). However, serum levels of testosterone in women with PV were comparable to those in patients in the nonerythrocytic group (PV: 20.5 ± 3.5 ng/mL versus non-erythrocytic group: 21.0 ± 4.3 ng/mL). Serum levels of testosterone were not related to serum levels of cholesterol. Therefore, we speculated that lower testosterone levels were not due to lower serum levels of cholesterol, a known adverse effect of statin. In conclusion, we report for the first time that serum levels of testosterone were lower in male PV patients than in those with RE; however, serum levels of testosterone in female patients with PV were not lower.

show abstract

“…BCa treated with exemestane developed erythrocytosis and the forth case involved 57-year-old postmenopausal lady with invasive ER ? BCa treated with neo-adjuvant chemotherapy followed by an anastrozole and developed secondary erythrocytosis along with raised testosterone levels and haematocrit became normal after cessation of anastrozole [5].…”

mentioning

confidence: 97%

A Case of Anastrozole-Induced Erythrocytosis

Kapoor

Singh

Agrawal

2018

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Dear Editor, Anastrozole, a third-generation aromatase inhibitor (AI) is used as adjuvant treatment for post-menopausal women with hormone receptor positive Breast Carcinoma (BCa). Common side effects associated with the use of Anastrozole are skeletal complications, sexual dysfunction, musculoskeletal pain, thromboembolism, cardiac and cerebrovascular disease [1]. We, however, report an unvisited adverse event; erythrocytosis induced with use of anastrozole in patient with BCa. A 65-year-old South Asian, post-menopausal, non-comorbid woman underwent left breast lumpectomy and was diagnosed with Estrogen and progesterone receptor positive BCa stage TxN 0 M 0 , for which she was treated with 6 cycles of Docetaxel, Cyclophosphamide, followed by radiotherapy and subsequently started on Anastrozole 1 mg once daily in July 2014. Prior commencing anastrozole, her haemoglobin, and haematocrit levels were 11.4 gm/dl and 34% respectively, while her other blood counts were normal. In December 2017, she was found to have raised haemoglobin and haematocrit levels of 18.6 gm/dl and 59.9% respectively, normal white blood counts of 5230/cumm, platelet counts of 156,000/cumm. She had no symptoms and was normal on physical examination with normal blood pressure. Further tests revealed a normal liver and kidney function tests, a normal serum erythropoietin [EPO] levels of 6.88 [reference 3.70-31.5]. Bone marrow

show abstract

Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer

Cited by 4 publications

References 11 publications

Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer

Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer

Serum Levels of Testosterone in Patients with Polycythemia Vera

A Case of Anastrozole-Induced Erythrocytosis

Contact Info

Product

Resources

About